AO

Annals of Oncology

Annals of Oncology is the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology. It publishes innovative cancer treatments and translational work related to oncology and precision medicine, with particular focus on systemic anticancer therapy, randomized trials, guidelines, molecular pathology, bioinformatics, modern statistics, and biotechnologies.

Looking to publish in Annals of Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Oncology
Impact Factor 65.4
Quartile Q1
Open Access Type Hybrid
ISSN 0923-7534
eISSN 1569-8041
Invitation Only No
Cost Range This journal has no page charges; open access publishing options are available.

Submission Instructions

Annals of Oncology accepts the following article types. Click on an article type to view submission instructions.

Original Articles

Cover Letter A cover letter is required and must state that the report is not under consideration elsewhere and that all named authors have agreed to its submission. The cover letter must confirm that the report is not under consideration for publication elsewhere and that all named authors have agreed to its submission.
Abstract An abstract is required. Abstract must be a summary of 300 words or less. Abstract must be structured. Abstract must use the headings Background, Patients and methods, Results, and Conclusion(s).
Manuscript Manuscript should generally be no longer than 4500 words excluding the manuscript heading, abstract, acknowledgements, funding, and references, with each table or figure including legends, captions, and footnotes counting as 150 words toward the total. Manuscript should generally be structured as introduction; methods-patients and methods-materials and methods-etc; results; discussion; acknowledgements; funding; disclosure; references. Manuscript must include highlights at submission with 3 to 5 bullet points of no more than 125 characters each covering only the core results, and authors using generative AI in the writing process must add a statement in a section entitled 'Declaration of Generative AI and AI-assisted technologies in the writing process' before the references list.
References References are unrestricted in number and do not contribute to the total word count. References must be listed in numbered order following Index Medicus style. In-text citations should use superscript reference numbers after author names, the reference list should list all authors when there are three or fewer and only the first three followed by et al. when there are four or more, and every text citation must appear in the reference list and vice versa.
Figures & Tables Original Articles should have no more than 6 tables and figures in total recommended. Each illustration must be submitted as a separate file with captions provided separately, while online-only supplementary material should be uploaded in separate files and described in the manuscript. Supplementary tables or figures must be named and numbered as S1, S2, etc. in both the manuscript and the file.
Reformat to Annals of Oncology using Livewrite Premium

Reviews

Cover Letter A cover letter is required. The cover letter must state that the report is not under consideration elsewhere and that all named authors have agreed to its submission.
Abstract An abstract is required. The abstract must be 300 words or fewer. The abstract is generally unstructured, except reviews involving data synthesis such as systematic reviews and meta-analyses should use a structured abstract. For data-synthesis reviews, the abstract should use headings such as Introduction, Materials and methods, Results, and Conclusions, and Reviews may substitute Design or Materials and methods for Patients and methods.
Manuscript Review manuscripts must not exceed 5000 words excluding the manuscript heading, abstract, references, acknowledgements, funding, tables, and figures. Articles should be divided into clearly defined sections, and the first page must contain the article type, title, author list, affiliation list, and manuscript social media information. Reviews require highlights at submission consisting of 3 to 5 bullet points of no more than 125 characters each, and any use of generative AI in writing must be disclosed in a section titled 'Declaration of Generative AI and AI-assisted technologies in the writing process' placed before the References list.
References References are unrestricted in number and are not counted in the total word count. References should follow numbered Index Medicus style. References must be listed in numbered order, cite all authors when there are three or fewer, and list the first three authors followed by et al. when there are four or more.
Figures & Tables Supplementary material for Reviews should be uploaded in separate files, each illustration must be submitted as a separate file, and captions to illustrations must be provided separately. Tables must be submitted as editable text rather than images, and all figures must be provided in an editable format.
Reformat to Annals of Oncology using Livewrite Premium

Letters To The Editor

Cover Letter A cover letter is required and must confirm that the submission is not under consideration elsewhere and that all named authors have agreed to its submission. The cover letter must state that the report is not under consideration for publication elsewhere and that all named authors have agreed to its submission.
Abstract Abstract is not required for Letters To The Editor. Letters To The Editor do not require an abstract, so no abstract length applies. Abstract is not required for Letters To The Editor. Abstract is not required for Letters To The Editor.
Manuscript Letters To The Editor should be no longer than 500 words. The title should either match the related Original Article or be a summarised version when the letter relates to a previous publication. The corresponding author's email address must be provided in brackets, and any use of generative AI in writing must be disclosed in a section titled 'Declaration of Generative AI and AI-assisted technologies in the writing process' placed before the References list.
References Letters To The Editor may include a maximum of five references. References must be listed in numbered order following Index Medicus style. In-text citations should use superscript reference numbers, references to abstracts and Letters To The Editor must be identified as such, and reference lists should name all authors when there are three or fewer or the first three followed by et al. when there are four or more.
Figures & Tables Letters To The Editor may include a maximum of one table or one figure if necessary. Each illustration must be submitted as a separate file with captions provided separately, while tables must be submitted as editable text. Tables must be editable text rather than images, and all figures must be provided in an editable format.
Reformat to Annals of Oncology using Livewrite Premium

In Brief Trial Updates

Cover Letter A cover letter is required. The cover letter must state that the report is not under consideration elsewhere and that all named authors have agreed to its submission.
Abstract An abstract is required. Abstract must be 300 words or less. Abstract must be structured. Abstract must use the headings Background, Patients and methods, Results, and Conclusion(s).
Manuscript Manuscript should generally be no longer than 1200 words, excluding manuscript heading, abstract, acknowledgements, funding, tables and figures, and references. Articles should be divided into clearly defined sections. Up to 6 keywords must be provided immediately after the abstract, a funding statement must be included before the disclosure section, the declarations tool output must be uploaded, and any use of generative AI in writing must be disclosed in a section titled 'Declaration of Generative AI and AI-assisted technologies in the writing process' placed before the References list.
References References must be listed in numbered order following Index Medicus style. In-text citations should use superscript reference numbers, references must be numbered in list order, and for works with four or more authors only the first three authors should be listed followed by et al.
Figures & Tables Tables and figures are limited to 3 in total. Extended material must be uploaded in separate files and described in the manuscript to allow proper linking. Each illustration must be submitted as a separate editable file with captions supplied separately, and tables must be submitted as editable text rather than images.
Reformat to Annals of Oncology using Livewrite Premium

Recent Publications

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study

R-H. Xu, B.C. Cho, M. Chen, K. Muro, L. Wyrwicz, B. Li, S. Gao, C. Hsu, A. Turpin, F. Lordick, E. Cha, Q. Wu, S. Kim, J. Cai, L. Zhang, J. Fan, L. Wang, K. Sully, L. Wang, K. Goodman, M.A. Shah, I. Chau

10.1016/j.annonc.2026.07.413
View Publication

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study

H. Wakelee, J.D. Spicer, S. Gao, M. Liberman, M. Tsuboi, T. Kato, K.-N. Chen, C. Dooms, M. Majem, G.L. Martinengo, O. Bylicki, D. Rodríguez-Abreu, B. Halmos, D.R. Jones, J.E. Chaft, M. Reck, E. Jensen, S.M. Keller, A. Samkari, M.C. Garassino

10.1016/j.annonc.2026.08.005
View Publication

ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer

T. Conroy, M. Ducreux

10.1016/j.annonc.2026.08.003
View Publication

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer

F. Facchinetti, L. Friboulet, L. Liao, M. Peroni, S. Nakazawa, L. Zullo, M. Aldea, F. Pecci, M. Makarem, I. Alonso Garcia, R. Minari, B. Tuladhar, K. Ngo, A. Da Silva, L. Bigot, I. Odintsov, M.K.A. Koivu, A. Leonetti, J. Samaniego, E. Bernard, D.J. Kwiatkowski, B. Ricciuti, J.K. Rotow, J. Luo, J. LoPiccolo, N. Florez, M.M. Awad, J. Remon, Y. Loriot, B. Besse, F. Barlesi, A. Italiano, D.A. Barbie, C.P. Paweletz, P.C. Gokhale, W.W. Feng, M. Tiseo, D. Planchard, A.T. Shaw, P.A. Jänne

10.1016/j.annonc.2026.08.004
View Publication

Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)

A.Y. Zhang, H. Thomas, S. Begbie, L. Cheung, K.N. Chi, S. Chowdhury, M. Frydenberg, C. Herberstein, L.G. Horvath, A.M. Joshua, N.J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, R.A. McLaughlin, S.A. North, F. Parnis, W. Parulekar, D.W. Pook, M.N. Reaume, S.K. Sandhu, A. Tan, T.H. Tan, A. Thomson, F. Vera-Badillo, S.G. Williams, R.R. Zielinski, M.R. Stockler, I.D. Davis, C.J. Sweeney

10.1016/j.annonc.2026.07.412
View Publication

Frequently asked questions

How long does it take to publish?

3 days from submission to first decision; 45 days from submission to acceptance for accepted papers (median).

Reformat to Annals of Oncology using Livewrite Premium

Is a cover letter required?

A letter is required with manuscript submission stating that the report is not under consideration elsewhere and that all named authors have agreed to submission. Pre-submission enquiries require a short cover letter.

Reformat to Annals of Oncology using Livewrite Premium

What are the publication costs?

This journal has no page charges. Open access publishing options are available.

Reformat to Annals of Oncology using Livewrite Premium

Research Topics

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Cancer Treatment and Pharmacology Gastric Cancer Management and Outcomes Lung Cancer Research Studies HER2/EGFR in Cancer Research Pancreatic and Hepatic Oncology Research Breast Cancer Treatment Studies Lymphoma Diagnosis and Treatment Genetic factors in colorectal cancer Advanced Breast Cancer Therapies Lung Cancer Diagnosis and Treatment Cholangiocarcinoma and Gallbladder Cancer Studies Hepatocellular Carcinoma Treatment and Prognosis Radiomics and Machine Learning in Medical Imaging Prostate Cancer Treatment and Research Cancer Diagnosis and Treatment Head and Neck Cancer Studies Diverse Scientific and Economic Studies Economic and Financial Impacts of Cancer CAR-T cell therapy research Colorectal and Anal Carcinomas Ovarian cancer diagnosis and treatment

Related Journals

TJ
The Journal of Climate Change and Health Elsevier BV
II
Internet Interventions Elsevier BV
Se
Seizure Elsevier BV
NB
npj Breast Cancer NATURE PORTFOLIO
AP
Academic Pediatrics Elsevier BV
HP
Health Policy Elsevier BV